OrbiMed’s Fate Therapeutics FATE Stock Holding History

OrbiMed’s Portfolio FATE Stock Details FATE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-1,680,580	Closed	-$1.33M	–	105
2025 Q1	$1.33M	Hold	1,680,580	–	–	0.03%	98
2024 Q4	$2.77M	Hold	1,680,580	–	–	0.06%	98
2024 Q3	$5.88M	Buy	1,680,580 +325,228	+24%	+$1.27M	0.11%	94
2024 Q2	$4.45M	Hold	1,355,352	–	–	0.09%	94
2024 Q1	$9.95M	Buy	1,355,352 +827,272	+157%	+$5.12M	0.18%	80
2023 Q4	$1.98M	Buy	+528,080	New	+$1.25M	0.04%	97
2016 Q2	–	Sell	-692,900	Closed	-$1.25M	–	143
2016 Q1	$1.25M	Hold	692,900	–	–	0.01%	134
2015 Q4	$2.33M	Hold	692,900	–	–	0.02%	117
2015 Q3	$3.69M	Hold	692,900	–	–	0.04%	115
2015 Q2	$4.48M	Hold	692,900	–	–	0.04%	120
2015 Q1	$3.39M	Hold	692,900	–	–	0.03%	121
2014 Q4	$3.48M	Hold	692,900	–	–	0.03%	115
2014 Q3	$3.53M	Hold	692,900	–	–	0.04%	116
2014 Q2	$4.37M	Hold	692,900	–	–	0.05%	115
2014 Q1	$6.75M	Sell	692,900 -9,100	-1%	-$70.3K	0.08%	106
2013 Q4	$4.41M	Buy	+702,000	New	+$4.42M	0.06%	99

Other funds holding FATE

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return

VPC

Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

OrbiMed's FATE Position: Q2 2025 in Review

OrbiMed sold out of Fate Therapeutics (FATE) in Q2 2025, closing a stake of 1,680,580 shares — an estimated $1.33M sold.

OrbiMed first reported a position in FATE in Q4 2013 and held it in 16 quarters. The position peaked at $9.95M in Q1 2024. 139 funds tracked by Wall St. Rank hold FATE as of Q2 2025.

OrbiMed reported no remaining Fate Therapeutics position as of Q2 2025 after selling out during the quarter.
OrbiMed sold 1,680,580 Fate Therapeutics shares in Q2 2025, an estimated $1.33M.
OrbiMed first reported a position in Fate Therapeutics in Q4 2013 and held it in 16 quarters.
OrbiMed's Fate Therapeutics position peaked at $9.95M in Q1 2024.
139 funds tracked by Wall St. Rank held Fate Therapeutics as of Q2 2025.

Based on OrbiMed's 13F filing for Q2 2025, filed 14 Aug 2025.